Sequence: NH2-RLTRKRGLKLAGGGGGRRRRRRRRR
| Experiment Id | EXP002440 |
|---|---|
| Paper | Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegen |
| Peptide | ApoB11-9R |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | intraperitoneal repeated dosing; exact siRNA mass not extracted from visible text |
| Mixing Ratio | 1:10 siRNA:ApoB11 |
| Formulation Format | peptide/siRNA electrostatic complex |
| Formulation Components | ApoB11 peptide + siα-syn |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | PDGF/α-syn transgenic mouse model of PD/DLB; non-transgenic mice also used for uptake controls |
| Administration Route | intraperitoneal injection, twice weekly for 4 weeks |
| Output Type | α-syn knockdown, neuronal protection, reduced neuroinflammation |
| Output Value | Reduced α-syn immunoreactivity by ~65–70% in neocortex, ~40–50% in hippocampus, and ~50–55% in striatum; western blot showed ~30–40% reduction in α-syn; ameliorated NeuN neuronal loss and TH fiber loss; reduced GFAP/Iba1 neuroinflammation |
| Output Units | |
| Output Notes | FITC-siα-syn delivered across BBB to neurons and astrocytes; ApoB11 localized to ~55–60% of NeuN+ neurons and ~20–25% of GFAP+ astrocytes |
| Toxicity Notes | No observable CNS toxicity stated for siα-syn delivery; study noted no TH loss/inflammation from partial knockdown |
| Curation Notes |